NCT00617565 is a Phase 3 clinical trial of biphasic insulin aspart in Diabetes, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT00617565?

NCT00617565 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT00617565?

Interventions in NCT00617565: biphasic insulin aspart, biphasic human insulin.

What condition does NCT00617565 study?

NCT00617565 studies Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2.

Is NCT00617565 still recruiting?

NCT00617565 is currently completed. Last updated 24 February 2017.

Last reviewed 2017-02-24 · How we verify

NCT00617565

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Completed Phase 3 Last updated 24 February 2017

What this trial tests

Phase 3 trial testing biphasic insulin aspart in Diabetes in 219 participants. Completed in 26 November 2003.

Timeline

8 July 2003

Primary endpoint
26 November 2003

26 November 2003

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	219
Start date	8 July 2003
Primary completion	26 November 2003
Estimated completion	26 November 2003
Sites	6 locations across China

Drugs / interventions tested

biphasic insulin aspart — full drug profile →
biphasic human insulin — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 18 to 70, any sex, with Diabetes or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Systematic literature review of use of blood glucose monitoring in phase III clinical studies of insulin analogs.
Miikkulainen K, Caruso A, Mast O, Zhang R, et al · · 2016 · cited 4× · PMID 27145817 · DOI 10.1186/s12902-016-0102-1

Verify or expand the search:

Other trials of biphasic insulin aspart

Trials testing the same drug.

NCT02762578 — Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes · Phase 3 · completed
NCT02648217 — Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in · Phase 3 · completed
NCT00659282 — Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes · completed
NCT00184626 — Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With · Phase 4 · completed
NCT00564668 — Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes · Phase 3 · completed

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00617565 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 24 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00617565.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing